In this context, a concentration‐dependent antiproliferative action of myricetin has been reported in human papillary thyroid cancer cells (SNU‐790), revealing cytotoxicity, causing DNA condensation, upregulating the Bax: Bcl‐2 ratio, inducing caspase cascades, modifying the mitochondrial membrane potential, and tempting the apoptosis‐inducing factors release [43]. The gene discussed is BCL2; the disease is thyroid gland papillary carcinoma.